Opinion: Boycotting Elsevier Is Not Enough

The publishing giant will likely survive the latest boycott by scientists. An overhaul is needed to make science publishing fair and open.

| 4 min read
boycott petition elsevier academic scholarly publishing open access

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

ABOVE: © ISTOCK.COM, LEREMY

All of this has happened before. A group of scientists, upset with the extraordinarily profitable Elsevier, have announced its intention to boycott the publisher. In 2012, mathematicians led the Cost of Knowledge boycott. This time, it’s University of California (UC) scientists upset about the breakdown of negotiations that sought to combine journal subscriptions with open-access publishing. Unfortunately, on its own, this boycott will do little to change science publishing.

Many scientists struggle to see the value Elsevier provides. Elsevier usually demands a high price to publish a paper—on the order of $4,000–$5,000—and has also shown a willingness to play hardball in negotiations with whole countries. Importantly, Elsevier’s authors, reviewers, and most editors never receive any of this money.

Boycotting Elsevier is therefore a reasonable response from dissatisfied stakeholders. In theory, if boycotters provide their authoring, reviewing, and editing expertise for publishers with better copyright and access ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Shaun Khoo

    This person does not yet have a bio.
Share
TS Digest January 2025
January 2025, Issue 1

Why Do Some People Get Drunk Faster Than Others?

Genetics and tolerance shake up how alcohol affects each person, creating a unique cocktail of experiences.

View this Issue
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo
New Frontiers in Vaccine Development

New Frontiers in Vaccine Development

Sino
New Approaches for Decoding Cancer at the Single-Cell Level

New Approaches for Decoding Cancer at the Single-Cell Level

Biotium logo
Learn How 3D Cell Cultures Advance Tissue Regeneration

Organoids as a Tool for Tissue Regeneration Research 

Acro 

Products

Artificial Inc. Logo

Artificial Inc. proof-of-concept data demonstrates platform capabilities with NVIDIA’s BioNeMo

Sapient Logo

Sapient Partners with Alamar Biosciences to Extend Targeted Proteomics Services Using NULISA™ Assays for Cytokines, Chemokines, and Inflammatory Mediators

Bio-Rad Logo

Bio-Rad Extends Range of Vericheck ddPCR Empty-Full Capsid Kits to Optimize AAV Vector Characterization

Scientist holding a blood sample tube labeled Mycoplasma test in front of many other tubes containing patient samples

Accelerating Mycoplasma Testing for Targeted Therapy Development